Skip to main content

Advertisement

Table 1 Antimicrobial susceptibility, production of β-lactamases, and pulsotype of the 69 isolates of A. baumannii analyzed in this study.

From: Growth in glucose-based medium and exposure to subinhibitory concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii

     MIC Method Phoenix (μg/ml)b    
Number of isolates Hospital Sample Source Ward/unita TE A/S CI AK GM PP PT AT CZ CP IP MP MIC IP (μg/ml) β-lactamases Pulsotype
2 S. Matteo Blood Medicine ≤2 8/4 >2 >32 >8 >64 >64/4 >16 >32 >16 ≤1 ≤1 0.5-1.0 AmpC, OXA-90, OXA-10 SMAL
6 S. Matteo Sputum Medicine ≤2 8/4 >2 >32 >8 >64 >64/4 >16 >32 >16 ≤1 ≤1 0.5-1.0 AmpC, OXA-90, OXA-10 SMAL
2 S. Matteo Urine Medicine 4 / >2 >32 >8 >64 >64/4 >16 >16 / 2 ≤1 0.5-1.0 AmpC, OXA-90, OXA-10 SMAL
6 S. Matteo Soft tissue swab Medicine 4 8/4 >2 >32 >8 >64 >64/4 >16 >16 >16 ≤1 ≤1 0.5-1.0 AmpC, OXA-90, OXA-10 SMAL, SMAL 2,
3 S. Matteo Bronchoaspirate Medicine / 8/4 >2 >32 >8 >64 >64/4 >16 >16 >16 ≤1 ≤1 0.5-1.0 AmpC, OXA-90, OXA-10 SMAL, SMAL 3
3 S. Matteo Urine Surgery 4 / >2 >32 >8 >64 >64/4 >16 >16 / 2 ≤1 0.5-1.0 AmpC, OXA-90, OXA-10 SMAL
8 S. Matteo Wound swab Surgery ≤2 8/4 >2 >32 >8 >64 >64/4 >16 >16 >16 ≤1 ≤1 0.5-1.0 AmpC, OXA-90, OXA-10 SMAL
8 S. Matteo Blood Surgery / / >2 >32 >8 >64 >64/4 >16 >16 / 2 ≤1 0.5-1.0 AmpC, OXA-90, OXA-10 SMAL, SMAL 1
1 S. Matteo Pus Surgery ≤2 8/4 >2 >32 >8 >64 >64/4 >16 >16 >16 ≤1 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
1 S. Matteo Sputum Surgery / 4/2 >2 >32 >8 >64 64/4 >16 >16 >16 ≤1 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
1 S. Matteo Soft tissue swab LTCU ≤2 / >2 >32 >8 >64 64/4 >16 >16 >16 ≤1 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
1 S. Matteo Sputum LTCU / / >2 >32 >8 >64 64/4 >16 >16 >16 2 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
1 S. Matteo Blood LTCU / / >2 32 >8 >64 64/4 >16 >16 >16 ≤1 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
2 S. Matteo Soft tissue swab Dermatology ≤2 / >2 >32 >8 >64 >64/4 >16 >16 >16 ≤1 ≤1 0.5-1 AmpC, OXA-90, OXA-10 SMAL
1 S. Matteo Pus Dermatology ≤2 8/4 >2 >32 >8 >64 >64/4 >16 >16 >16 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
2 S. Matteo Wound swab Ambulatory / / >2 >32 >8 >64 >64/4 >16 >16 >16 4 2 2 AmpC, OXA-90, OXA-10 SMAL
1 S. Matteo Urine Ambulatory ≤2 / >2 >32 >8 >64 >64/4 >16 >16 / ≤1 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
2 S. Matteo Wound swab Urology ≤2 / >2 >32 >8 >64 >64/4 >16 >16 >16 ≤1 ≤1 0.5 AmpC, OXA-90, OXA-10 SMAL
2 S. Matteo Urine Nephrology / / >2 >32 >16 >64 >64/4 >16 >16 / ≤1 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
1 S. Matteo Blood Haematology 8 / >2 >32 >8 >64 >64/4 >16 >16 16 ≤1 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
1 S. Maugeri Bronchoaspirate PRU 8 / >2 >32 >8 >64 >64/4 >16 >16 / ≤1 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
7 S. Maugeri Urine NRU / / >2 >32 >8 >64 64/4 >16 >16 / ≤1 ≤1 1 AmpC, OXA-90, OXA-10 SMAL
2 S. Maugeri Skin swab NRU / 8/4 >2 >32 >8 >64 >64/4 >16 >16 >16 ≤1 ≤1 0.5 AmpC, OXA-90, OXA-10 SMAL
1 S. Maugeri Bronchoaspirate NRU ≤2 / >2 >32 >8 >64 64/4 >16 >32 / ≤1 ≤1 0.5-1 AmpC, OXA-90, OXA-10 SMAL
1 S. Maugeri Urine ORU ≤2 8/4 >2 >32 >8 >64 >64/4 >16 >32 / ≤1 ≤1 0.5 AmpC, OXA-90, OXA-10 SMAL
1 S. Maugeri Skin swab ORU ≤2 8/4 >2 >32 >8 >64 64/4 >16 >32 / ≤1 ≤1 0.5 AmpC, OXA-90, OXA-10 SMAL
2 S. Maugeri Urine FRU ≤2 8/4 >2 >32 >8 >64 >64/4 >16 >32 >16 ≤1 ≤1 0.5 AmpC, OXA-90, OXA-10 SMAL
  1. a PRU, pulmonary rehabilitation unit; NRU, neurological rehabilitation unit; ORU, oncological rehabilitation unit. b TE, tetracicline; A/S, ampicillin/sulbactam; CI, ciprofloxacin; AK, amikacin; GM, gentamicin; PP, piperacillin; PT, piperacillin/tazobactam; AT, aztreonam; CZ, ceftazidime; CP, cefepime; IP, imipenem; MP, meropenem. Ditto marks indicate that the β-lactamase pattern was identical for all the strains tested.